Medicare's GLP-1 Bridge starts July 1. Here's who qualifies…

Medicare has long been prohibited by law from covering medications specifically for weight loss. The Medicare GLP-1 Bridge works around that restriction by operating outside the standard Part D benefit as a Section 402 demonstration — a CMS authority that allows short-term payment experiments.

This is not permanent coverage. CMS originally planned to follow the Bridge with a longer-term program called the BALANCE Model, which was scheduled to begin in Medicare Part D in 2027 and run through 2031. CMS announced in April 2026 that the BALANCE Model in Medicare Part D is indefinitely delayed, in part because major Part D plan sponsors declined to participate. The Bridge has been extended to December 31, 2027 as a result.

What happens to Medicare GLP-1 coverage for obesity after December 31, 2027 is not currently determined. KFF, which analyzed the program in May 2026, called this a meaningful risk — beneficiaries could gain coverage under the Bridge and then lose it in 2028 with no confirmed replacement pathway.

The Bridge operates nationally, in all states and territories.

CMS has specified three GLP-1 products eligible under the Bridge, when prescribed for weight management:

• Foundayo® (orforglipron) — all formulations
• Wegovy® (semaglutide) — both injectable and tablet formulations
• Zepbound® (tirzepatide) — KwikPen formulation only. The single-dose vial and single-dose pen formulations of Zepbound are not covered under the Bridge.

These are all FDA-approved drugs. CMS updated the drug list in April 2026 to add Foundayo following its FDA approval.

If you already receive one of these drugs through your Part D plan for a covered indication — such as type 2 diabetes, obstructive sleep apnea, or cardiovascular disease risk reduction — you continue to use your Part D plan for that prescription. The Bridge is specifically for the weight management indication.

You must be enrolled in an eligible Medicare Part D plan type: a standalone prescription drug plan (PDP) or a Medicare Advantage plan with drug coverage (MA-PD), including Special Needs Plans and employer group waiver plans. Dually eligible beneficiaries (Medicare and Medicaid) who are in eligible plan types may also participate.

You are not eligible if you are enrolled only in a private fee-for-service plan, a PACE organization, a section 1876 cost contract, a section 1833 health care prepayment plan, a fallback plan, or a religious fraternal benefit plan — unless you are also separately enrolled in a standalone PDP.

Clinical criteria. For your provider to submit a successful prior authorization, you must meet at least one of the following at the time you initiated GLP-1 therapy:

• BMI of 35 or above, OR
• BMI of 30 or above with a diagnosis of at least one of: heart failure with preserved ejection fraction; uncontrolled hypertension (systolic above 140 mmHg or diastolic above 90 mmHg despite two antihypertensive medications); or chronic kidney disease stage 3a or above, OR
• BMI of 27 or above with a diagnosis of at least one of: pre-diabetes (per American Diabetes Association guidelines); previous myocardial infarction; previous stroke; or symptomatic peripheral artery disease.

Important note on timing: The clinical criteria apply at the time you initiated GLP-1 therapy — not at the time of the prior authorization request. If you started a GLP-1 in 2024 with a BMI of 37 and your BMI is now 32, you may still qualify based on your BMI when you started treatment. Your provider can attest to this in the prior authorization form.

Who is not eligible for the Bridge — even if they otherwise qualify: If you have type 2 diabetes, obstructive sleep apnea, or noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis), your GLP-1 prescription is eligible for coverage through your Part D plan. You would access it that way, not through the Bridge. The Bridge is designed only for beneficiaries whose GLP-1 prescription is for weight management and not covered by another Part D benefit.

Nothing, for now. CMS says beneficiaries do not need to register or opt in to the program. When you pick up a prescription for an eligible GLP-1 on or after July 1, your provider will receive a request to submit a prior authorization form. CMS will provide additional details on that process before the launch date.

If you currently take one of the covered drugs out of pocket, talk to your prescriber before July 1 about whether you qualify. Ask them to be ready to submit a prior authorization once the program opens.

If you use Extra Help (Low-Income Subsidy). The LIS cost-sharing subsidy does not apply to Bridge copays. The $50/month is a fixed cost regardless of your subsidy status. For some low-income beneficiaries, this may still be a financial barrier. KFF flagged this as an equity concern in its May 2026 analysis of the program.

The $50 copay is separate from your normal Part D benefit. The Part D deductible does not apply to drugs furnished through the Bridge. The $50 you pay each month does not count toward your true out-of-pocket (TrOOP) costs or your Part D out-of-pocket maximum.

Manufacturers have agreed to provide eligible drugs at a net price of $245 per month. Pharmacies are reimbursed by a central CMS processor, and manufacturers provide rebates to cover the difference between the drug's wholesale acquisition cost and the $245 net price.

This structure means the Bridge does not operate through your individual Part D plan. Part D plan sponsors do not bear financial risk for Bridge costs and do not need to opt in.

After December 31, 2027. The Bridge expires, and the BALANCE Model in Medicare Part D is indefinitely delayed. There is currently no confirmed path forward for Medicare coverage of GLP-1s for obesity after 2027. KFF describes this as setting up a real possibility that beneficiaries gain access through the Bridge and then lose it in 2028.

Which pharmacies will participate. CMS is finalizing these details. Additional information is expected before July 1. The prior authorization process will be managed centrally, not through individual Part D plans.

Low-income beneficiaries. The fixed $50 copay with no subsidy may make the program functionally inaccessible for some of the lowest-income Medicare beneficiaries, even if they otherwise qualify.

State Medicaid programs. The BALANCE Model is ongoing for Medicaid, with implementation on a rolling basis through January 2027. Coverage details and eligibility may vary by state. This article covers Medicare only.

• Do I meet the Medicare GLP-1 Bridge clinical criteria based on my BMI and medical history at the time I started GLP-1 therapy?
• If I have type 2 diabetes, sleep apnea, or cardiovascular disease, does that mean I stay on my Part D plan rather than using the Bridge?
• Which pharmacy should I use, and has that pharmacy confirmed it will participate in the Bridge?
• What happens to my coverage after December 31, 2027?
• Does the $50/month copay count toward anything on my Part D plan?

• CMS updates at cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge — this page has been updated regularly and more details are expected in June 2026
• Your prescriber's readiness to submit a prior authorization request once the program opens July 1
• Your Part D plan's communications about the Bridge, including any pharmacy network details

The Medicare GLP-1 Bridge is a significant but time-limited change for Medicare beneficiaries who have been unable to afford GLP-1 medications for weight management. It is not permanent, it does not apply to everyone on Medicare, and it comes with real limitations — especially for low-income beneficiaries who will not receive the normal Extra Help subsidies.

If you are on Medicare, enrolled in a Part D plan, and think you may meet the clinical criteria, this is worth discussing with your prescriber now — before July 1 — so you are ready when the program opens.

Medical disclaimer: This content is for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Sources

• CMS, Medicare GLP-1 Bridge overview page. cms.gov
• CMS, Medicare GLP-1 Bridge — Information for Medicare Beneficiaries. cms.gov
• CMS Press Release, May 6, 2026. "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." cms.gov
• KFF, May 11, 2026. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge." kff.org